DRUG today
$23.00+$2.30 (+11.11%)close Nov 6, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourStrong Bullish
15 minBearish
5 minStrong Bullish
Daily trend turns up above $59.71
Key levels
Resistance$31.80
Resistance$24.00
Support$17.40
Support$0.94
Latest news & SEC filings
LegalLaw firms investigate Bright Minds Biosciences after FDA partial clinical hold
AnalystBaird keeps Bright Minds Biosciences at Outperform, cuts price target
AnalystBaird keeps Outperform rating on Bright Minds Biosciences, cuts target to $107
AnalystBTIG keeps Buy rating on Bright Minds Biosciences, cuts price target to $37
AnalystBTIG kept its Buy rating on Bright Minds Biosciences (DRUG) with a price target of $37.
All DRUG news →About Bright Minds Biosciences
Bright Minds Biosciences is a clinical-stage biotechnology company that develops serotonergic therapeutics. Its lead compound, BMB-101, targets neurological and psychiatric conditions. The company operates in Canada and the United States, conducting research, preclinical testing, and clinical trials. None of its drug candidates have received marketing clearance from health authorities.
Based on the company's 20-F filed Dec 31, 2024.
Nasdaq · Healthcare
BRIGHT MINDS BIOSCIENCES INC. (DRUG)
What Is the Price Target for DRUG?
SEPT Low Target
$127.50
SEPT Mid Target
$150.00
SEPT High Target
$172.50
Analyst Consensus
$150.00
Is DRUG a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DRUG.
Start Free Trial →Is DRUG Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$150.00
5
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with DRUG?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →DRUG Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for DRUG
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for DRUG, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:16:59 | $23.00 | 1,847 | $$42K | BUY |
| 20:27:00 | $22.83 | 1,510 | $$34K | SELL |
| 19:27:36 | $23.10 | 1,000 | $$23K | BUY |
| 18:29:28 | $23.16 | 1,100 | $$25K | BUY |
| 18:27:47 | $23.16 | 1,000 | $$23K | MIDPOINT |
5 dark pool trades shown · $$149K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BRIGHT MINDS BIOSCIENCES INC. (DRUG) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →DRUG — frequently asked questions
What is DRUG stock price today?
BRIGHT MINDS BIOSCIENCES INC. (DRUG) is at $23.00, up 11.11% (+$2.30) at the Nov 6, 2026 close.
Why is DRUG stock moving today?
Latest DRUG news — Nov 7, 2026: Law firms investigate Bright Minds Biosciences after FDA partial clinical hold · Nov 4, 2026: Baird keeps Bright Minds Biosciences at Outperform, cuts price target
What is the DRUG price target?
The average analyst price target for DRUG is $150.00, ranging from $145 to $220, based on 5 analysts. Latest: Bright Minds Biosciences upgrade on Oct 15, 2026.
What do analysts rate DRUG?
Analyst ratings for DRUG: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did DRUG beat earnings?
DRUG last reported on Aug 17, 2026: EPS -$0.17 vs -$1.22 expected — a beat of 86.1%.
What are DRUG support and resistance levels?
Support: $17.40, $0.94. Resistance: $24.00, $31.80, $38.00.
What are insiders doing with DRUG?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on DRUG?
Nov 7, 2026: Law firms investigate Bright Minds Biosciences after FDA partial clinical hold · Nov 4, 2026: Baird keeps Bright Minds Biosciences at Outperform, cuts price target · Nov 3, 2026: Baird keeps Outperform rating on Bright Minds Biosciences, cuts target to $107